» Articles » PMID: 12461031

Synergic Activity of Cephalosporins Plus Fluoroquinolones Against Pseudomonas Aeruginosa with Resistance to One or Both Drugs

Overview
Date 2002 Dec 4
PMID 12461031
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Owing to increasing resistance in Pseudomonas aeruginosa, empirical drug regimens may include agents to which some strains may be resistant. The purpose of this study was to evaluate the in vitro activities of different combinations of cephalosporin plus fluoroquinolone against P. aeruginosa isolates with varying susceptibility to the study drugs. Broth microdilution susceptibility testing was performed with 10 clinical isolates of P. aeruginosa. The bactericidal activity of cefepime or ceftazidime alone and in combination with ciprofloxacin, levofloxacin, gatifloxacin or moxifloxacin was evaluated using time-kill methods. Colony counts were determined at 0, 4, 8 and 24 h, using antimicrobial concentrations of 0.5 x MIC. All procedures were performed in duplicate. Synergy was defined as a >2-log decrease in cfu/mL at 24 h compared with the single most active agent. The MICs for tested strains were: ceftazidime 0.75-32, cefepime 0.125-8, ciprofloxacin 0.0078-8, levofloxacin 0.023-16, gatifloxacin 0.023-16 and moxifloxacin 0.0521-32 mg/L. Four strains were susceptible to all drugs, two strains were cephalosporin susceptible and fluoroquinolone resistant, and two strains were cephalosporin resistant and fluoroquinolone susceptible. Two strains were resistant or intermediately susceptible to all drugs. Various cephalosporin and fluoroquinolone combinations were synergic against P. aeruginosa, including strains resistant to one or both agents in combination. No synergy was observed in two strains susceptible to all drugs. There were no differences noted between different cephalosporin and fluoroquinolone combinations. Concentrations used in this study are clinically achievable with recommended regimens in most cases.

Citing Articles

Addressing the global challenge of bacterial drug resistance: insights, strategies, and future directions.

Karnwal A, Jassim A, Mohammed A, Al-Tawaha A, Selvaraj M, Malik T Front Microbiol. 2025; 16:1517772.

PMID: 40066274 PMC: 11891257. DOI: 10.3389/fmicb.2025.1517772.


Post-COVID-19 cavitary lung lesion due to and in a patient suffering from COVID-19 pneumonia - a case report.

Rajpal K, Kumar S, Saurabh K, Kumari N, Kumar R, Kumar R Access Microbiol. 2023; 5(6):acmi000457.

PMID: 37424552 PMC: 10323781. DOI: 10.1099/acmi.0.000457.


The Potential of Antibiotics and Nanomaterial Combinations as Therapeutic Strategies in the Management of Multidrug-Resistant Infections: A Review.

Adeniji O, Nontongana N, Okoh J, Okoh A Int J Mol Sci. 2022; 23(23).

PMID: 36499363 PMC: 9736695. DOI: 10.3390/ijms232315038.


Combination antibiotic therapy versus monotherapy in the treatment of acute exacerbations of chronic obstructive pulmonary disease: an open-label randomized trial.

Nguyen Thi Thu P, Huong M, Tran Thi N, Thanh H, Minh K BMC Infect Dis. 2021; 21(1):1019.

PMID: 34587911 PMC: 8480084. DOI: 10.1186/s12879-021-06687-3.


Fluoroquinolone-Transition Metal Complexes: A Strategy to Overcome Bacterial Resistance.

Ferreira M, Gameiro P Microorganisms. 2021; 9(7).

PMID: 34361943 PMC: 8303200. DOI: 10.3390/microorganisms9071506.